Rubicon Research

Kotak Mutual Fund and Motilal Mutual Fund have jointly invested approximately ₹169 crore in Rubicon Research Ltd, acquiring a 2.25% stake ahead of the company's Initial Public Offering (IPO). This strategic move underscores the growing interest in India's pharmaceutical sector, with Rubicon's upcoming IPO aiming to raise ₹1,377.5 crore to fund debt repayment and strategic growth initiatives.

Rubicon Research posted a remarkable 69% increase in its profit for the June quarter, highlighting robust operational performance and strategic market expansion. The growth is driven by increased sales across key pharmaceutical segments, efficient cost management, and improved supply chain operations. Analysts note that this performance reflects the company’s ability to capitalize on rising demand for specialized formulations while maintaining healthy margins.